Author Archives: Joana Carvalho

Algernon’s NP-120 Surpasses Merck’s MK-7264 in Reducing Cough Frequency in Animal Model of Acute Cough, Study Shows

Algernon Pharmaceuticals‘s NP-120 (ifenprodil) outperformed Merck‘s MK-7264 (gefapixant) in an animal model of acute cough, a preclinical study by a contract research organization (CRO) shows. NP-120 is Algernon’s repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), while MK-7264 is Merck’s lead candidate for the treatment…